Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Protein Found to Control Inflammatory Response
Disease Discoveries

Protein Found to Control Inflammatory Response

By Nora DunneAug 19, 2015
Share
Facebook Twitter Email
Like humans, mice with cryopyrinopathy, an autoinflammatory disease triggered by a mutation in the NLRP3 gene, suffer from body-wide excessive inflammation, visible in dark violet-stained immune cells in the liver and skin (left). In contrast, inflammation is not detected in mice that express POP1 in immune cells (right).

A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.

Autoinflammatory diseases occur when inflammation, the body’s reaction to infections and injuries, is over-activated. The new paper, published in Immunity, describes how POP1 blocks a pro-inflammatory mediator called IL-1b.

“Inflammation is controlled by a complex network of regulators that is still poorly understood,” said senior author Christian Stehlik, PhD, John P. Gallagher Research Professor of Rheumatology. “Here, we describe a novel inhibitor of the inflammatory response.”

Stehlik worked with co-senior author Andrea Dorfleutner, PhD, research assistant professor in Medicine-Rheumatology, and a team headed by postdoctoral fellow Lucia de Almeida, PhD. They found that mice expressing POP1 were protected from systemic inflammation. Those mice also recovered more quickly than controls from inflammatory diseases, including peritonitis, sepsis and cryopyrinopathy.

Interestingly, the scientists also discovered that human patients with cryopyrinopathy and sepsis have less POP1 in their immune cells than others.

christian-stehlik
Christian Stehlik, PhD, John P. Gallagher Research Professor of Rheumatology, led a study describing how the POP1 protein inhibits inflammatory responses.

“Based on this finding, we developed a proof-of-principle drug based on POP1 and administered this treatment for peritonitis in a mouse model,” Dorfleutner said. “We found significantly reduced inflammation.”

The scientists believe that treatments based on POP1 could improve many inflammatory diseases, not just the ones tested in this study.

“A better understanding of the molecular events that contribute to autoinflammatory diseases is critical for the development of novel therapies that may benefit patients in the future,” said Stehlik, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Understanding the critical role of POP1 in inflammation leads us to believe that novel POP1-based therapies may be applicable in humans.”

In a previous study, Stehlik and colleagues showed how another protein in the POP family, POP3, inhibits the immune response to virus infection. Unlike POP1, POP3 did not affect autoinflammatory disease. POP proteins are unique in their function to regulate specific aspects of the immune response.

The Stehlik lab worked in collaboration with Harris Perlman, PhD, Solovy/Arthritis Research Society Professor in Medicine-Rheumatology and Alexander Misharin, MD, PhD, research assistant professor in Medicine-Pulmonary, at Feinberg, as well as David Greaves, PhD, at the University of Oxford and Hal Hoffmann, MD, at the University of California, San Diego.

This research was supported by National Institutes of Health grants GM071723, HL097183, AI092490, AI082406, AI099009, AI120625, AR064349, AR057532, AR066739, AR050250, AR054796, AI092490, HL108795, AR061593 and AI52430; Cancer Center Support Grant CA060553; Skin Disease Research Center grant AR057216; American Heart Association grant 13GRNT17110117; an ATS/Scleroderma Foundation; and British Heart Foundation grant RG/10/15/28578.

Immunology Research
Share. Facebook Twitter Email

Related Posts

Understanding How Hormones Influence Anemia

May 25, 2023

Groundbreaking Geneticist Delivers Epigenetics Lecture

May 24, 2023

CT Scan Best at Predicting Heart Disease Risk in Middle Age

May 23, 2023

Comments are closed.

Latest News

Celebrating Advances in Alzheimer’s Research and Clinical Care

May 26, 2023

Understanding How Hormones Influence Anemia

May 25, 2023

Groundbreaking Geneticist Delivers Epigenetics Lecture

May 24, 2023

CT Scan Best at Predicting Heart Disease Risk in Middle Age

May 23, 2023

Investigating the Benefits of Salt Substitutes in Elderly Patients

May 22, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230506_NM569
20230506_NM564
20230506_NM563
20230506_NM559
20230506_NM555
20230506_NM549
20230506_NM508
20230506_NM474
20230506_NM136
20230506_NM124
20230506_NM118
20230506_NM094

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.